Division of Bayer AG
Latest From Algeta ASA
European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.
The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.
The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.
Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Bayer AG
- Senior Management
Andrew Kay, Pres. & CEO
Roger Harrison, PhD, CBO
Andreas Menrad, PhD, CSO
- Contact Info
Phone: (47) 23 00 79 90
Kjelsasveien 172 A
P.O. Box 54 Oslo, NO-0411
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.